Format

Send to

Choose Destination
JAMA Ophthalmol. 2019 Oct 3:1-9. doi: 10.1001/jamaophthalmol.2019.3914. [Epub ahead of print]

Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy.

Author information

1
Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California.
2
Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, Bethesda, Maryland.
3
Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California.
4
Division of Retinal Disorders and Ophthalmic Genetics, Stein Eye Institute, David Geffen School of Medicine, UCLA (University of California, Los Angeles).
5
The Vision Center, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, California.
6
USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles.
7
Retina Department Genomics Institute, Mejora Vision MD/Virtual Eye Care MD, Mérida, Yucatán, México.
8
Laboratoire de Diagnostic Moleculaire, Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada.
9
Department of Paediatric Surgery, Montreal Children's Hospital, McGill University and McGill University Health Centre Research Institute, Montreal, Quebec, Canada.
10
Department of Human Genetics and Ophthalmology, Montreal Children's Hospital, McGill University and McGill University Health Centre Research Institute, Montreal, Quebec, Canada.
11
Center for Advanced Retinal and Ocular Therapeutics, University of Pennsylvania, Philadelphia.
12
F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia.

Abstract

Importance:

Next-generation sequencing can detect variants of uncertain significance (VUSs), for some of which gene therapy would not be advantageous. Therefore, the pathogenicity of compound heterozygous or homozygous variants should be confirmed before bilateral vitrectomy and administration of voretigene neparvovec-rzyl.

Objective:

To describe an in vitro mutagenesis assay for assessing the pathogenicity of variants in the RPE65 gene.

Design, Setting, and Participants:

This case series was conducted at 2 tertiary referral centers. Clinical history, imaging, and electrophysiologic testing results were reviewed from September 5, 2008, to December 31, 2019. Participants were 4 pediatric patients with Leber congenital amaurosis who were evaluated for or met the inclusion criteria for phase 1 to 3 clinical trials or were referred for voretigene neparvovec-rzyl treatment.

Main Outcomes and Measures:

A functional assay was used to confirm the pathogenicity of novel RPE65 VUSs in 4 patients with Leber congenital amaurosis.

Results:

Four patients with Leber congenital amaurosis had VUSs in RPE65. Patients 1 and 2 were siblings with the homozygous VUS c.311G>T p.(G104V). Patient 3 was a compound heterozygote with 1 known pathogenic allele, c.1202_1203insCTGG p.(Glu404AlafsTer4), and 1 VUS, c.311G>T p.(G104V), which segregated to separate alleles. Patient 4 was also a compound heterozygote with 1 pathogenic variant, c.11 + 5G>A, and 1 variant in trans, c.1399C>T p.(P467S). In vitro mutagenesis revealed that the G104V and P467S RPE65 proteins were catalytically inactive (0% isomerase activity). Patients 1 and 2 were excluded from participation in a phase 1 trial owing to high Adeno-associated virus 2 capsid-neutralizing antibodies. Patients 3 (G104V) and 4 (P467S) underwent successful surgical gene therapy with voretigene neparvovec-rzyl, and their response to lower white light intensity and visual field increased in fewer than 30 days after gene therapy intervention.

Conclusions and Relevance:

Findings from this study suggest that, in patients with missense mutations in RPE65, functional assays of protein function can be performed to assess the pathogenicity of variants in both compound heterozygous and homozygous cases. Given the potential risks of gene therapy operations, in vitro RPE65 activity testing should be considered to avoid the possibility of treating a false genotype.

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center